PlumX Metrics
Embed PlumX Metrics

Respiratory Syncytial Virus in Transplant: Stopping the Short-Term Spread, Solving the Longer-Term Problems

Emerging Transplant Infections: Clinical Challenges and Implications, Page: 725-741
2021
  • 0
    Citations
  • 0
    Usage
  • 1
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Book Chapter Description

Respiratory syncytial virus (RSV) causes significant morbidity and mortality in immunocompromised hosts with particular burden among allogeneic hematopoietic stem cell transplant and lung transplant recipients. Affected patients have a substantial risk of secondary infection, ICU admission, or death. Improved diagnostic testing with better sensitivity has given new insights into the epidemiology of disease. In particular, it has highlighted the issue of nosocomial transmission and hospital outbreaks. These can be challenging to manage. Currently, treatment options include ribavirin and immunoglobulin replacement. Definitive evidence of the efficacy of this approach is limited. Given the significant impact of this common infection in this at-risk patient population, research is ongoing into new strategies for prevention and treatment. These range from new antiviral therapies targeting different steps of the replication cycle to monoclonal antibodies and vaccines.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know